Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Drugs Made In America Acquisition EV-to-OCF?
Drugs Made In America AcquisitionDMAA +0.09%14 EV-to-OCF is -685.61 as of Jul. 26, 2026. GuruFocus rates DMAA with a GF Score™ of 14/100. The stock has 1 warning sign investors should review. Among 545 Diversified Financial Services companies, Drugs Made In America Acquisition ranks better than 87.16% on this metric.
DMAA'
s EV-to-OCF Range Over the Past 10 Years
Min: -685.61 Med: 0 Max: -685.61
Current: -685.61
During the past 2 years, the highest EV-to-OCF of Drugs Made In America Acquisition was -685.61. The lowest was -685.61. And the median was .
DMAA's EV-to-OCF is ranked better than 87.16% of 545
companies
in the Diversified Financial Services industry
Industry Median: -32.19
vs DMAA: -685.61
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Drugs Made In America Acquisition (NAS:DMAA) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Drugs Made In America Acquisition's PE Ratio (TTM) for today is calculated as:
Drugs Made In America Acquisition's share price for today is $10.70.
Drugs Made In America Acquisition's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.200.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Drugs Made In America Acquisition EV-to-OCF Related Terms
Drugs Made In America Acquisition EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Shell Companies subindustry, Drugs Made In America Acquisition's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Drugs Made In America Acquisition EV-to-OCF vs Diversified Financial Services Industry
For the Diversified Financial Services industry and Financial Services sector, Drugs Made In America Acquisition's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Drugs Made In America Acquisition's EV-to-OCF falls into.
Drugs Made In America Acquisition's current Enterprise Value is $259.85 Mil.
Drugs Made In America Acquisition's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.38 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Drugs Made In America Acquisition (DMAA) has a EV-to-OCF of -685.61 as of Jul. 26, 2026. According to the industry distribution chart, Drugs Made In America Acquisition ranks #70 out of 545 companies in the Diversified Financial Services industry, placing it in the top 12.8%.
Is Drugs Made In America Acquisition's EV-to-OCF too high?
Drugs Made In America Acquisition's current EV-to-OCF is -685.61. Based on the distribution chart, Drugs Made In America Acquisition ranks #70 out of 545 companies in the Diversified Financial Services industry, which is in the top quartile — a strong position relative to peers. Overall, Drugs Made In America Acquisition has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Drugs Made In America Acquisition's EV-to-OCF compare to PLMK and TRGS?
According to the Diversified Financial Services industry distribution chart, Drugs Made In America Acquisition ranks #70 out of 545 companies for EV-to-OCF. This places Drugs Made In America Acquisition in the top 13% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Diversified Financial Services company?
A good EV-to-OCF depends on the Diversified Financial Services industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Drugs Made In America Acquisition's current EV-to-OCF is -685.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Drugs Made In America Acquisition stock overvalued right now?
Drugs Made In America Acquisition (DMAA) has a current EV-to-OCF of -685.61. The current EV-to-OCF is -685.61. Drugs Made In America Acquisition's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Drugs Made In America Acquisition (DMAA), the current EV-to-OCF is -685.61 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Drugs Made In America Acquisition Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DMAA has been successfully added to your 
